A method for identifying binding targets of bioactive molecules based on dual-ended photoaffinity probes
Through the base complementary pairing and binding technology of the two-head photoaffinity probe, the problems of low sensitivity and non-specific binding of target identification in the prior art are solved, and efficient identification of low abundance and low affinity targets are achieved, which significantly improves the Accuracy of target identification.
Patent Information
- Application Number
- CN202011486161.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-12-16
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-12-16
AI Technical Summary
When existing photoaffinity labeling techniques analyze targets of biologically active small molecules, the probe structure skeleton is branched, resulting in limited sensitivity and non-specific binding, and the inability to comprehensively and accurately identify low abundance and low affinity targets.
Using a double-headed photoaffinity probe, the double-headed binding probe and the double-headed capture probe are used in groups. The bases of the probe skeleton are complementary and paired together. The two sides of the probe are bound to bind biologically active molecules to capture both sides of the probe. Combining photoaffinity molecules, an excitation light crosslinking reaction is used to form a specific "probe-protein" complex to improve the sensitivity and accuracy of target identification.
It significantly improves the recognition ability of low abundance and low affinity targets, reduces non-specific interactions, improves the sensitivity and accuracy of target identification, and is suitable for the study of biologically active small molecule binding targets.
Smart Images

Figure CN112630446B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, and relates to a method for identifying a bioactive molecule binding target, and in particular to a method for identifying a bioactive molecule binding target based on a double-headed photoaffinity probe. Background Art
[0002] Photoaffinity labeling (PAL) combines the advantages of modern molecular biology, cell biology, medicinal chemistry, analytical chemistry and other disciplines. It uses synthetic photoaffinity probe molecules to produce highly active intermediates under the irradiation of light of a specific wavelength, which can directly and irreversibly covalently cross-link with proteins that specifically bind to drug molecules to achieve the capture of drug target protein molecules. Using photoaffinity labeling technology, a large number of disease-related targets have been discovered, and the modes of action of various small molecules and biomacromolecules have been determined. This information is of great significance to rational drug design, such as the discovery of new drug targets or a new explanation of the function of a known protein. This is self-evidently significant for clarifying the occurrence, development and treatment of diseases at the molecular level.
[0003] The design of photoaffinity labeling probes plays a decisive role in the implementation of photoaffinity labeling technology. However, when using classic common linker skeletons (such as lysine, polyethylene glycol, alkyl chain skeletons, etc.) to analyze the binding targets of some bioactive small molecules, the overall structural skeleton of the probe is branched, so its sensitivity is limited and non-specific binding exists, making it impossible to comprehensively and accurately identify its target (Salisbury, CM and FB Cruatt (2008). "Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes." J Am Chem Soc 130 (7): 2184-2194; Smith, E. and I. Collins (2015). "Photoaffinity labeling in target-and binding-site identification." Future Med Chem 7 (2): 159-183).
[0004] In order to solve the above technical problems, the inventors developed and improved the existing probes (Wang, DY, Y.Cao, LYZheng, LDChen, XFChen, ZYHong, ZYZhu, X.Li and YFChai (2017). "Target Identification of Kinase Inhibitor Alisertib (MLN8237) by Using DNA-Programmed Affinity Labeling." Chemistry 23 (45): 10906-10914.) and provided a photoaffinity probe set, which consists of a binding probe and a capture probe. The two probes are base-complementary paired or specifically bound. One side of the binding probe binds to the bioactive molecule, and one side of the capture probe binds to the photoaffinity molecule. When performing target identification, the binding probe and the capture probe are hybridized separately, a certain concentration of the probe is taken and incubated with the sample, and it is placed under a photoaffinity molecule excitation light source for irradiation to stimulate the photocrosslinking reaction, so that the capture probe effectively anchors the relevant target protein to form a "probe-protein" complex.
[0005] Compared with current probe molecules, single-head probes have the following advantages due to their concentrated structural skeleton and flexible structure: significantly increased sensitivity and improved recognition of low-abundance and low-affinity target protein pairs. However, cells are full of hydrophobic and electrostatic interactions, and thousands of proteins with different biophysical properties and abundances. Therefore, weak or transient non-specific interactions are prevalent. With the development of proteomics and protein spectrum identification technology, the number of potential bioactive small molecule binding proteins identified has increased significantly, and verification one by one is difficult and inefficient. Therefore, how to optimize the single-head probe target analysis method to reduce non-specificity while ensuring sensitivity is of great significance for small molecule target analysis. Summary of the invention
[0006] The purpose of the present invention is to study the double-ended photoaffinity probe in view of the defects of the single-ended probe, and thus provide a method for identifying the binding target of a bioactive molecule based on the double-ended photoaffinity probe. The specific scheme is as follows:
[0007] The present invention provides a method for identifying a bioactive molecule binding target based on a double-ended photoaffinity probe, comprising the following steps:
[0008] S1. Preparation of double-ended photoaffinity probe
[0009] Taking groups as units, each group consists of a double-ended binding probe and a double-ended capture probe; the probe backbone of the double-ended binding probe is base-complementarily paired or specifically bound to the probe backbone of the double-ended capture probe; the same biologically active molecules are bound to both sides of the probe backbone of the double-ended binding probe, and the same photoaffinity molecules are bound to both sides of the probe backbone of the double-ended capture probe.
[0010] The two ends of the probe skeleton are modified with amino groups and then reacted with activated esters of bioactive molecules or photoaffinity molecules to obtain double-headed binding probes and double-headed capture probes, which are purified and characterized before use.
[0011] S2. Protein sample preparation
[0012] Extract protein samples from biological samples, test the content and purity, and then enrich them;
[0013] S3. Capture, separation and identification of bioactive small molecule binding targets
[0014] 3.1 Capture:
[0015] The double-headed binding probe and the double-headed capture probe are hybridized separately, a certain concentration of the double-headed photoaffinity probe is taken and incubated with the protein sample, and then placed under the photoaffinity molecule excitation light source to stimulate the photocrosslinking reaction, so that the capture probe can effectively anchor the relevant target protein, and the double-headed binding probe and the double-headed capture probe can specifically bind to form a "protein-probe-protein" covalent complex;
[0016] 3.2 Extraction:
[0017] After the unbound free proteins are initially removed from the mixed sample, the resulting precipitate is dried and dissolved; after the "protein-probe-protein" complex is purified and enriched, the free probe is removed;
[0018] 3.3 Isolation and identification:
[0019] After dissolving the sample in step 3.2, a certain method is used to separate the bioactive small molecule binding target, and the target is identified to obtain the bioactive molecule binding target.
[0020] Preferably, in S1, the probe skeleton is a DNA skeleton, an RNA skeleton or a polypeptide skeleton; the biological molecules include small molecules, aptamers, polysaccharides, polypeptides or proteins; the photoaffinity molecules include aromatic azides, diazomethanes or benzophenones; the double-headed capture probe is connected to a biological reaction amplification system, and the biological reaction amplification system can select the commonly used biotinylated base T, and the biotinylated base T is synthesized using the Click reaction.
[0021] Preferably, in S1,
[0022] The preparation process of the double-headed binding probe is as follows: first, prepare the carboxyl or sulfonyl derivatives of the biologically active small molecules, and use the EDC / NHS coupling reaction to prepare the activated esters of the above derivatives; secondly, modify the amino groups at both ends of the probe skeleton, and further use the condensation reaction of the amino groups and the activated esters to synthesize the double-headed binding probe.
[0023] The preparation process of the double-headed capture probe is as follows: first, prepare the carboxyl or sulfonyl derivatives of the photoaffinity molecule, and use the EDC / NHS coupling reaction to prepare the activated ester of the above derivative; secondly, modify the amino groups at both ends of the probe skeleton, and further use the condensation reaction of the amino group and the activated ester to synthesize the double-headed capture probe.
[0024] The dual-ended photoaffinity probe was purified by a combination of ethanol precipitation and chromatographic separation:
[0025] Ethanol precipitation: Measure the volume of the mixed solution, first add one-tenth volume of sodium acetate with a pH of 5.0 and a concentration of 3 mol / L, then add one-tenth volume of 7.5 mg / mL glycogen, and then add 2 to 3 times the volume of anhydrous ethanol, mix well and place at -80°C for at least 2 hours; take out the sample, centrifuge at 17000g at 4°C, discard the supernatant, add 70% pre-cooled ethanol to the precipitate, shake and wash, and centrifuge at 17000g at 4°C; dry the obtained precipitate and dissolve it in triethylamine acetate buffer, and perform preparative chromatography purification.
[0026] Preparative chromatography: Preparative high performance liquid chromatography was used; mobile phase: phase A: 0.1 mol / L triethylamine acetate buffer; phase B: acetonitrile; chromatographic column: Agilent ZORBAX XDB C18 column; detection wavelength: 210-400 nm; after elution, vacuum freeze-drying was used, and the concentration was determined by ultra-micro fluorescence spectrophotometer after reconstitution with ultrapure water.
[0027] The purified probe is characterized by purity and molecular weight before use.
[0028] Preferably, in S2, the protein sample is derived from cultured cells, animal tissues or human samples. The protein sample extraction method includes lysate extraction, repeated freeze-thaw method or ultrasonic extraction method.
[0029] Preferably, in S3, the separation method of the biologically active small molecule binding target comprises electrophoretic separation or high performance liquid chromatography separation; the identification of the biologically active small molecule binding target comprises immunoblotting technology or protein spectrum identification technology; the verification of the biologically active small molecule binding target comprises surface plasmon resonance testing, isothermal titration calorimetry testing, cell thermal transition analysis testing or drug affinity target stability testing.
[0030] The beneficial protection and effects of the present invention are as follows:
[0031] Through experiments, it was found that the double-headed photoaffinity probe prepared according to the method of the present invention has high purity and the measured molecular weight is close to the theoretical molecular weight, which meets the actual detection needs.
[0032] The present invention finds that by using a double-headed photoaffinity probe, whole-cell protein complexes can be extracted, and specific binding targets can be visualized through ultraviolet light capture and polyacrylamide gel electrophoresis separation technology, which greatly reduces the non-specificity of target identification. It can be used for the identification of binding targets of bioactive small molecules and help discover new disease binding targets, and has good application prospects.
[0033] By verifying the target identification of the biological small molecule MLN8237, the method of the present invention can effectively identify the specific binding targets and non-specific binding targets of MLN8237; compared with the single-head photoaffinity probe, the sensitivity and accuracy of the target identification of the double-head photoaffinity probe of the present invention are better. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 These are the characterization results of the double-headed DNA photoaffinity probe: A is the mass spectrometry identification result of the double-headed binding probe, B is the purity test result of the double-headed binding probe, C is the mass spectrometry identification result of the double-headed capture probe, and D is the purity test result of the double-headed capture probe.
[0035] Figure 2 Comparison of the capture of AuroraA, tubulin and HSP60 in whole cell protein extracts by MLN8237 single-ended and double-ended DNA photoaffinity probes: A is a schematic diagram of the two probe forms, B is a single-ended and double-ended DNA photoaffinity probe with a base length of 16 bp, and C is a single-ended and double-ended DNA photoaffinity probe with a base length of 100 bp.
[0036] Figure 3 These are the target validation results of MLN8237, A is the Tubulin binding surface plasmon resonance identification result, and B is the HSP60 binding surface plasmon resonance identification result. DETAILED DESCRIPTION
[0037] The present invention will now be described in detail in conjunction with the embodiments and drawings, but the implementation of the present invention is not limited thereto.
[0038] The reagents and raw materials used in the present invention are all commercially available or can be prepared according to literature methods. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by volume.
[0039] The target identification process of the biological small molecule MLN8237 with a relatively clear target is taken as an example to describe the identification process in the present invention.
[0040] Example 1: Preparation, purification and characterization of dual-ended photoaffinity probes
[0041] 1. Preparation of dual-ended photoaffinity probes
[0042] The double-ended photoaffinity probe is composed of a double-ended binding probe and a double-ended capture probe. The double-ended binding probe has a similar structure to the double-ended capture probe. Figure 2 A, both include a probe skeleton located in the middle and active molecules and a biological reaction amplification system bound to both sides of the skeleton.
[0043] The probe backbone of the double-ended binding probe binds to the same bioactive molecule on both sides, the probe backbone of the double-ended capture probe binds to the same photoaffinity molecule on both sides, and the probe backbone of the double-ended binding probe is complementary to or specifically binds to the probe backbone of the double-ended capture probe.
[0044] In this embodiment, the probe backbone includes but is not limited to a DNA backbone, an RNA backbone, a polypeptide backbone, etc.; the biological molecules include but are not limited to small molecules, aptamers, polysaccharides, polypeptides, proteins, etc.
[0045] (1) Preparation of double-ended binding probes:
[0046] First, the carboxyl or sulfonyl derivatives of the biologically active small molecule MLN8237 are prepared, and the activated esters of the above derivatives are prepared by EDC / NHS coupling reaction; secondly, the 5' and 3' ends of the DNA binding chain are amino-modified, wherein the 5' end uses 5' amino TFA (CAS No.: 133975-85-6, English name 5'-amino-modifier-C6-TFACEP), and the 3' end directly uses C7 amino solid phase carrier (CB No.: CB8356712, English name 3'-DMT-TC6(NH-FMOC)-CPG), and conventional primers are used for synthesis; further, the amino group and the activated ester condensation reaction are used to synthesize the double-headed binding probe.
[0047] The synthetic route of the binding probe of the biologically active small molecule MLN8237 is as follows:
[0048]
[0049] (2) Preparation of double-ended capture probes:
[0050] First, the biotinylated base T was synthesized using the Click reaction as a biological reaction amplification system.
[0051] Secondly, the 5' and 3' ends of the DNA capture strand were modified with amino groups, and then 4-azidobenzoic acid activated ester was prepared by EDC / NHS coupling reaction, and further the synthesis was carried out by condensation reaction between amino groups and activated ester.
[0052] The synthetic route of the capture probe is as follows:
[0053]
[0054] In actual synthetic applications, the capture of biologically active small molecules binding targets includes but is not limited to the above-mentioned phenyl azide ultraviolet light free radical cross-linking capture, including but not limited to aromatic azides, diazomethanes, benzophenones, etc.
[0055] (3) Probe purification: ethanol precipitation followed by preparative chromatography
[0056] Ethanol precipitation: measure the volume of the mixed solution, first add one-tenth volume of 3 mol / L sodium acetate (pH 5.0), then add one-tenth volume of 7.5 mg / mL glycogen, and then add 2.5 times the volume of anhydrous ethanol, mix well and place at -80°C for at least 2 hours; take out the sample, centrifuge at 17000g for 15 min at 4°C, discard the supernatant, add 70% pre-cooled ethanol to the precipitate, shake and wash, and centrifuge at 17000g for 5 min at 4°C; dry the obtained precipitate and dissolve it in triethylamine acetate buffer for preparative chromatography purification.
[0057] Preparative chromatography: System: Agilent 1200 preparative high performance liquid chromatography. Mobile phase: Phase A: 0.1 mol / L triethylamine acetate buffer (TriethylamineAcetate, TEAA); Phase B: acetonitrile. Chromatographic column: Agilent ZORBAX XDBC18 chromatographic column (4.6 mm × 250 mm, 5 μm). Detector: Multi-wavelength UV detector (210 nm to 400 nm). After elution, vacuum freeze-dry, reconstitute with ultrapure water, and measure its concentration using an ultra-micro fluorescence spectrophotometer.
[0058] (4) Characterization of probes:
[0059] Purity determination: The purity of the probe was determined by high performance liquid chromatography, with 0.1% formic acid water and 0.1% formic acid acetonitrile as the mobile phase, 0-15min, 5%-95% organic phase ratio large gradient elution, full wavelength ultraviolet detection, and the probe purity was calculated based on the chromatographic peak area in the chromatogram. The purity should be greater than 95%.
[0060] Molecular weight determination: Matrix-assisted laser desorption ionization time-of-flight mass spectrometry was used to determine the molecular weight distribution of the probe for characterization and identification. The matrix used was a mixed solution of A:B=8:1, where A was a 50 mg / ml 3-hydroxypropionaldehyde acetonitrile aqueous solution (the volume ratio of acetonitrile to water was 1:1), and B was a 50 mg / mL ammonium citrate aqueous solution.
[0061] In this example, a 100 bp MLN8237-double-headed DNA photoaffinity probe was synthesized by aminocarboxyl coupling reaction, and the molecular weight was further determined by mass spectrometry, and the purity was detected by reverse phase chromatography. The relevant information of the binding probe and capture probe in the MLN8237 photoaffinity probe is summarized in Table 1:
[0062] Table 1 MLN8237 photoaffinity probe information
[0063]
[0064] The mass spectrometry identification results of the combined probes are shown in Figure 1 A, the measured molecular weight of the combined probe is 32645.10, which is very close to the theoretical molecular weight. The purity test results are shown in Figure 1 B. The probe purity was calculated based on the peak area in the chromatogram, which was 97.3%. The mass spectrometry identification results of the capture probe can be found in Figure 1 C, the measured molecular weight is 31444.26, the purity test results are shown in Figure 1 D, purity is 98.2%, both meet the requirement of greater than 95%.
[0065] Example 2 Target identification and verification
[0066] 1. Extraction of whole cell protein samples
[0067] (1) Cell culture and pretreatment:
[0068] Human hepatoma cell Hep3B was cultured in a DMEM high-glucose medium containing 10% fetal bovine serum, 0.1 mg / mL streptomycin, and 100 U / mL penicillin in a cell culture incubator at a constant temperature of 37°C and 5% CO2. When the cells grew to about 80% confluence, 0.25% trypsin was used to digest the cells, and an appropriate amount of serum-containing medium was added to terminate the digestion. The cells were centrifuged at 1000 g for 3 min, the supernatant was discarded, and the cells were resuspended in PBS and centrifuged at 1000 g for 3 min, and washed once.
[0069] (2) Protein extraction:
[0070] The cells were resuspended in western and IP cell lysis buffer, placed in liquid nitrogen for 3 minutes, placed in a 37°C water bath for 5 minutes, repeated 3 times, centrifuged at 12000g for 5 minutes, and the supernatant was collected. Observe and compare the trypan blue staining under a microscope before and after protein extraction.
[0071] (3) Content and purity determination:
[0072] Content determination: The protein concentration was determined using a commercial BCA concentration determination kit according to the instructions. The diluted standard and the sample to be tested were added to a 96-well plate, and an equal amount of BCA reaction reagent was added. The plate was incubated at 37°C for 20 minutes, and the absorbance of the 96-well plate was read by a microplate reader at a wavelength of 562 nm, and calculated according to the standard curve.
[0073] Purity determination: Take an equal amount of protein, add sodium acetate, glycogen, and anhydrous ethanol according to the above-mentioned ethanol precipitation method, centrifuge to obtain nucleic acid precipitate, add appropriate amount of ultrapure water to dissolve, and use Thermo nanodrop to determine its concentration, calculate and compare the nucleic acid content, and further use a commercial DEAE adsorption column to equilibrate at room temperature for 2 minutes, and centrifuge at 12000g for 5 minutes to remove DNA impurities.
[0074] Protein enrichment: Use an ultrafiltration tube with a cutoff parameter of 0.3KDa, centrifuge at 12000g for 2 minutes, and elute.
[0075] 2. Capture, separation and identification of bioactive small molecule binding targets
[0076] (1) Capture:
[0077] The binding probe and the capture probe are hybridized separately, and a certain concentration of double-headed DNA photoaffinity probe is incubated with the protein sample on a shaker at 4°C. It is placed under an ultraviolet point light source with an irradiation wavelength of 365nm and an irradiation temperature of 4°C to stimulate the photocrosslinking reaction, so that the probe can effectively anchor the relevant target protein to form a "protein-DNA-protein" covalent complex.
[0078] (2) Extraction:
[0079] The above mixed sample is used for preliminary removal of other unbound free proteins by ethanol precipitation method, and the obtained precipitate is dried and dissolved in phosphate buffer or ultrapure water; the "protein-DNA-protein" complex is purified and enriched by "biotin-streptavidin" magnetic bead method, and the elution method is optimized; the free probe is removed by ultrafiltration, and the obtained liquid is vacuum-lyophilized for subsequent research.
[0080] (3) Separation and identification:
[0081] Add an appropriate amount of ultrapure water to the above sample, add 5× protein loading buffer according to 1 / 4 volume and boil. Use polyacrylamide gel electrophoresis, separation, membrane transfer, antibody incubation, scanning imaging and other steps. The experimental steps are detailed in the related literature of the prior art.
[0082] 3. Verification of biologically active small molecules binding targets
[0083] Surface plasmon resonance analysis to validate the binding of bioactive small molecules to their binding targets: using BiacoreTM T200 instrument (GE Health).
[0084] Protein coupling: The protein was coupled to the CM5 chip using the amino coupling method. The working buffer was PBS, and the coupled protein was diluted with 10mM NaAc to a final concentration of 200μg / mL. The chip surface was treated with 0.2M EDC and 50mM NHS in a 1:1 mixture at a flow rate of 10μL / min for 7 minutes, the protein solution was injected for 7 minutes, and the activated chip surface was blocked with pH 8.5, 1M ethanolamine for 7 minutes.
[0085] Initial screening: The sample was diluted with PBS to 500 μM compound containing 5% DMSO, and then diluted to 50 μM compound. The sample was injected at a flow rate of 30 μL / min for 30 s to observe the binding state of the compound and the protein.
[0086] Kinetic experiment: Prepare a 50μM high concentration compound containing 5% DMSO, then dilute it by 2 times to obtain a series of concentration gradients. The working buffer is PBS buffer containing 5% DMSO. The sample is injected at a flow rate of 30μL / min for 60s or 120s, and the dissociation time is 300s for kinetic experiments. The obtained data are fitted and analyzed using the kinetic model or stable binding model in the Biacore T200 evaluation software. The larger the signal response value and the lower the Kd value, the stronger the physical binding between the active component and its target protein.
[0087] 4. Experimental results
[0088] 4.1 Target identification results
[0089] MLN8237, also known as Alecetin, has become a clinical candidate drug because it can specifically inhibit Aurora Kinase A. The two bind to the ATP binding region shared by kinase proteins, so MLN8237 can theoretically bind to a variety of other kinases or proteins. The binding targets of MLN8237 have been identified using the original single-head old method. They are Aurora Kinase A (AuroraA) for specific binding, α-tubulin 8 (tubulin) and Heat shock protein (HSP60) for non-specific binding.
[0090] Comparison of the capture of AuroraA, tubulin, and HSP60 in cell whole protein extracts by MLN8237 single-head and double-head DNA photoaffinity probes: the probe working concentration was 0.1μM, the total cell protein was 500mg, incubated for 2h, UV irradiated for 30s, after photocrosslinking, protein loading buffer was added, metal bath at 95℃ for 10min, and the above three proteins were detected by immunoblotting.
[0091] The results are as follows Figure 2 As shown in the figure, in the 16bp sequence, the new double-head method is no different from the original single-head old method. The captured sample only contains "AuroraA-DNA", "tubulin-DNA" and "HSP60-DNA". This may be due to the steric hindrance that prevents the two ends of the short-chain probe from being anchored to the protein at the same time ( Figure 2 B); however, in the 100bp sequence of 100T (Mw is about 30KDa), the immunoblotting results show that the "Aurora A-DNA-AuroraA" complex is present, but not "tubulin-DNA-tubulin" and "HSP60-DNA-HSP60", but "AuroraA-DNA", "tubulin-DNA", "HSP60-DNA" complexes are present ( Figure 2 C), indicating that the new double-headed method can quickly determine the binding target of biologically active small molecules by the similarities and differences of the proteins at both ends. When the two ends are the same, it is a specific binding target, and when the two ends are different, it is a non-specific binding target.
[0092] 4.2 Target Verification
[0093] according to Figure 3 , surface plasmon resonance tests showed that Tubulin ( Figure 3 A) and HSP60( Figure 3 B) The binding response to MLN8237 increases with the concentration of MLN8237, showing a linear relationship, indicating non-specific binding, which is the same as the target identification results of other methods.
[0094] The above examples only illustrate the overall experimental process through individual methods, but in actual application, it is not limited to this. For example, the preparation method of protein samples is not limited to the use of Western and IP cell lysate extraction, including but not limited to the use of a variety of lysate lysis (RIPA, NP-40, SDS and 1% Triton X-100, etc.), the use of repeated freeze-thaw method, the use of ultrasonic extraction method, etc. The source of protein samples includes but is not limited to the use of cultured cells, animal tissues, human samples, etc.
[0095] The separation of biologically active small molecules binding targets includes but is not limited to the above-mentioned electrophoresis techniques and high performance liquid chromatography techniques, including but not limited to paper electrophoresis, polyacrylamide gel electrophoresis, sodium dodecyl sulfate polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, agarose gel electrophoresis, isoelectric focusing electrophoresis, capillary electrophoresis, ion exchange high performance liquid chromatography, molecular exclusion chromatography, reversed phase high performance liquid chromatography, normal phase high performance liquid chromatography, hydrophilic high performance liquid chromatography, etc.
[0096] The identification of biologically active small molecule binding targets includes but is not limited to the above-mentioned immunoblotting technology, and includes but is not limited to protein spectrum identification technology.
[0097] The verification of the binding target of the biologically active small molecule includes but is not limited to the above-mentioned surface plasmon resonance test, includes but is not limited to isothermal titration calorimetry test, cell thermal transition analysis test, drug affinity target stability test, etc.
[0098] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. A method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe, characterized in that: The steps include: S1. Preparation of double-ended photoaffinity probe The double-ended photoaffinity probe is composed of a double-ended binding probe and a double-ended capture probe; the probe skeleton of the double-ended binding probe is base-complementarily paired or specifically bound to the probe skeleton of the double-ended capture probe; the probe skeleton of the double-ended binding probe is bound to the same biologically active molecule on both sides, and the probe skeleton of the double-ended capture probe is bound to the same photoaffinity molecule on both sides. The two ends of the probe skeleton are modified with amino groups and then reacted with the biologically active molecule or photoaffinity molecule to produce an activated ester reaction, respectively obtaining a double-headed binding probe and a double-headed capture probe, which are purified and characterized for later use. The probe skeleton is a 100 bp DNA skeleton, and the biologically active molecule is MLN8237. S2. Protein sample preparation Extract protein samples from biological samples, test the content and purity, and then enrich them; S3. Capture, separation and identification of bioactive molecules binding targets 3.1 Capture: The double-headed binding probe and the double-headed capture probe are hybridized separately, and a certain concentration of the double-headed photoaffinity probe is incubated with the protein sample, and then placed under the photoaffinity molecule excitation light source to stimulate the photocrosslinking reaction, so that the capture probe can effectively anchor the relevant target protein to form a "protein-probe-protein" covalent complex; 3.2 Extraction: After the unbound free proteins are initially removed from the mixed sample, the resulting precipitate is dried and dissolved; after the "protein-probe-protein" complex is purified and enriched, the free probe is removed; 3.3 Isolation and identification: After the sample in step 3.2 is dissolved, a certain method is used to separate the "protein-probe-protein" complex, and the "protein-probe-protein" complex is identified. If the proteins at both ends of the probe are consistent, it is a bioactive molecule target. If the proteins at both ends of the probe are inconsistent, it is non-specific binding, and then the bioactive molecule binding target is obtained. The bioactive molecule binding target is Aurora kinase A; The identification method is not a disease diagnosis or treatment method.
2. The method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe according to claim 1, characterized in that: in, In S1, the photoaffinity molecules include aromatic azides, diazomethanes or benzophenones; and the double-headed capture probe is connected to a biological reaction amplification system.
3. The method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe according to claim 2, characterized in that: in, In S1, the preparation process of the double-headed binding probe is as follows: First, carboxyl or sulfonyl derivatives of biologically active small molecules are prepared, and activated esters of the above derivatives are prepared by EDC / NHS coupling reaction; second, amino groups are modified at both ends of the probe skeleton, and further condensation reaction between amino groups and activated esters is used to synthesize double-headed binding probes; The preparation process of the double-ended capture probe is as follows: First, carboxyl or sulfonyl derivatives of photoaffinity molecules are prepared, and activated esters of the above derivatives are prepared by EDC / NHS coupling reaction; secondly, amino groups are modified at both ends of the probe skeleton, and further condensation reaction of amino groups with activated esters is used to synthesize double-headed capture probes.
4. The method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe according to claim 2, characterized in that: in, The biological reaction amplification system is biotinylated base T, and the biotinylated base T is synthesized by using Click reaction.
5. The method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe according to claim 1, Features: The purification of the double-headed photoaffinity probe is carried out by combining ethanol precipitation and chromatographic separation: Ethanol precipitation: Measure the volume of the mixed solution, first add one-tenth volume of sodium acetate with a pH of 5.0 and a concentration of 3 mol / L, then add one-tenth volume of 7.5 mg / mL glycogen, and then add 2 to 3 times the volume of anhydrous ethanol, mix well and place at -80°C for at least 2 hours; take out the sample, centrifuge at 17000g at 4°C, discard the supernatant, add 70% pre-cooled ethanol to the precipitate, shake and wash, and centrifuge at 17000g at 4°C; dry the obtained precipitate and dissolve it in triethylamine acetate buffer, and perform preparative chromatography purification. Preparative chromatography: preparative high performance liquid chromatography was used; mobile phase: phase A: 0.1 mol / L triethylamine acetate buffer; phase B: acetonitrile; chromatographic column: Agilent ZORBAX XDB C18 chromatographic column; detection wavelength: 210-400 nm; after elution, vacuum freeze-drying was used, and the concentration was determined by ultra-micro fluorescence spectrophotometer after reconstitution with ultrapure water. The purified probe was characterized by purity and molecular weight and then used for later use.
6. The method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe according to claim 1, characterized in that: in, In S2, protein samples come from cultured cells, animal tissues or human samples. Protein sample extraction methods include lysis solution extraction, repeated freeze-thaw method or ultrasonic extraction method.
7. The method for identifying biologically active molecules binding targets based on a double-ended photoaffinity probe according to claim 1, characterized in that: in, In S3, the separation method of the bioactive molecule binding target comprises electrophoretic separation or high performance liquid chromatography separation; Identification of bioactive molecule binding targets includes immunoblotting or protein profiling techniques; Validation of target binding by bioactive molecules includes surface plasmon resonance testing, isothermal titration calorimetry, cellular thermal transition analysis, or drug affinity target stability testing.
Citation Information
Patent Citations
Preparation for Rv2645 protein, and application thereof on aspects of tuberculosis diagnosis and reorganized BCG vaccines
CN104292315A
Bovine theileria annulata indirect ELISA antibody detection kit and preparation method thereof
CN105866421A
Activated alkyne modified surface glass material used for biomolecule fixing, and surface modification method
CN110092592A
Protein molecule weak interaction capture magnetic bead based on photoaffinity covalent linkage as well as preparation method and application thereof
CN111004329A
Double-head triple-helix nucleic acid probe and method for detecting chloramphenicol by using same
CN111855992A
